Total Payments
$3,836
2022 Payments
$16.90
Companies
31
Transactions
277
Medicare Patients
717
Medicare Billing
$33,514
Payment Breakdown by Category
Food & Beverage$3,824 (99.7%)
Education$12.12 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,824 | 275 | 99.7% |
| Education | $12.12 | 2 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $511.98 | 37 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $464.49 | 25 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $392.45 | 39 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $356.53 | 31 | $0 (2018) |
| GlaxoSmithKline, LLC. | $326.98 | 24 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $191.98 | 14 | $0 (2018) |
| PFIZER INC. | $184.17 | 14 | $0 (2018) |
| AbbVie, Inc. | $168.75 | 10 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $155.35 | 10 | $0 (2018) |
| Amgen Inc. | $120.38 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $16.90 | 1 | Novo Nordisk Inc ($16.90) |
| 2019 | $502.92 | 33 | Novo Nordisk Inc ($151.67) |
| 2018 | $1,561 | 108 | AstraZeneca Pharmaceuticals LP ($177.41) |
| 2017 | $1,755 | 135 | AstraZeneca Pharmaceuticals LP ($261.31) |
All Payment Transactions
277 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/14/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Diabetes | ||||||
| 07/24/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2019 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $11.03 | General |
| Category: Respiratory | ||||||
| 07/11/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $16.28 | General |
| Category: Neuroscience | ||||||
| 06/27/2019 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Diabetes | ||||||
| 06/21/2019 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), ASMANEX, STEGLATRO | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/20/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: Central Nervous System (CNS) | ||||||
| 06/19/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Education | In-kind items and services | $7.12 | General |
| Category: Central Nervous System (CNS) | ||||||
| 06/17/2019 | Teva Pharmaceuticals USA, Inc. | AJOVY (Drug) | Food and Beverage | In-kind items and services | $12.96 | General |
| Category: Central Nervous System | ||||||
| 06/11/2019 | Valeritas, Inc. | V-GO (Device) | Food and Beverage | In-kind items and services | $68.18 | General |
| Category: 1 | ||||||
| 06/11/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Neuroscience | ||||||
| 05/30/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Vyvanse (Drug) | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: Central Nervous System (CNS) | ||||||
| 05/21/2019 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: Diabetes | ||||||
| 05/17/2019 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug), STEGLUJAN | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: ENDOCRINOLOGY | ||||||
| 05/08/2019 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $12.19 | General |
| Category: Cardiovascular | ||||||
| 04/25/2019 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: Diabetes | ||||||
| 04/17/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $12.82 | General |
| Category: Neuroscience | ||||||
| 04/16/2019 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Diabetes | ||||||
| 04/15/2019 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BOOSTRIX | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: VACCINES | ||||||
| 04/15/2019 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $9.02 | General |
| Category: Diabetes | ||||||
| 04/08/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Neuroscience | ||||||
| 04/03/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/02/2019 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $12.20 | General |
| Category: Diabetes | ||||||
| 03/14/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Neuroscience | ||||||
| 03/11/2019 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 164 | 234 | $21,113 | $6,612 |
| 2022 | 10 | 201 | 328 | $28,147 | $8,776 |
| 2021 | 7 | 180 | 315 | $30,291 | $10,193 |
| 2020 | 7 | 172 | 238 | $26,547 | $7,933 |
Total Patients
717
Total Services
1,115
Medicare Billing
$33,514
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 42 | $9,744 | $2,778 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 37 | $5,772 | $2,231 | 38.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 22 | 40 | $440.00 | $336.00 | 76.4% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 20 | 24 | $1,224 | $314.88 | 25.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 22 | 31 | $1,705 | $313.85 | 18.4% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 19 | 26 | $1,196 | $247.52 | 20.7% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 13 | 15 | $690.00 | $246.90 | 35.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 17 | 19 | $342.00 | $144.59 | 42.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 30 | 49 | $11,368 | $3,498 | 30.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 55 | $8,580 | $3,310 | 38.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 19 | 33 | $1,683 | $436.78 | 26.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 22 | 40 | $2,200 | $417.31 | 19.0% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 18 | 33 | $1,518 | $316.49 | 20.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2022 | 13 | 18 | $828.00 | $299.17 | 36.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 20 | 26 | $468.00 | $200.10 | 42.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 22 | 42 | $462.00 | $124.44 | 26.9% |
| 82043 | Urine microalbumin (protein) level | Office | 2022 | 15 | 16 | $512.00 | $91.82 | 17.9% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2022 | 15 | 16 | $528.00 | $82.33 | 15.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 41 | 83 | $12,948 | $4,569 | 35.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 44 | $10,208 | $3,936 | 38.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 27 | 47 | $2,585 | $496.32 | 19.2% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2021 | 25 | 37 | $1,887 | $495.43 | 26.3% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 19 | 38 | $1,748 | $368.98 | 21.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 21 | 27 | $486.00 | $209.79 | 43.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 23 | 39 | $429.00 | $117.00 | 27.3% |
About Dr. Norma Escamilla, DO
Dr. Norma Escamilla, DO is a Family Medicine healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1730223017.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Norma Escamilla, DO has received a total of $3,836 in payments from pharmaceutical and medical device companies, with $16.90 received in 2022. These payments were reported across 277 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($3,824).
As a Medicare-enrolled provider, Escamilla has provided services to 717 Medicare beneficiaries, totaling 1,115 services with total Medicare billing of $33,514. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Fort Worth, TX
- Active Since 02/19/2007
- Last Updated 08/20/2019
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1730223017
Products in Payments
- FARXIGA (Drug) $313.43
- JANUVIA (Drug) $297.93
- Victoza (Drug) $254.34
- INVOKAMET (Drug) $160.57
- SYMBICORT (Drug) $133.00
- Ozempic (Drug) $128.38
- Synthroid (Drug) $121.78
- BREO (Drug) $121.57
- INVOKANA (Drug) $109.76
- ANORO (Drug) $108.45
- JARDIANCE (Drug) $106.78
- Tresiba (Drug) $100.93
- XARELTO (Drug) $86.20
- SOLIQUA (Drug) $86.10
- Trintellix (Drug) $85.18
- Vascepa (Drug) $85.17
- Belviq (Drug) $80.31
- LYRICA (Drug) $74.84
- TRELEGY ELLIPTA (Drug) $70.85
- PRALUENT (Drug) $69.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Fort Worth
Robert Campbell, D.o, D.O
Family Medicine — Payments: $354,620
Family Medicine $354,620
Dr. Alex Guevara, D.o, D.O
Family Medicine — Payments: $75,300
Family Medicine $75,300
Dr. Michael Carletti, D.o, D.O
Family Medicine — Payments: $48,058
Family Medicine $48,058
Dr. Peter Damico, M.d, M.D
Family Medicine — Payments: $47,108
Family Medicine $47,108
Randall Richwine, Do, DO
Family Medicine — Payments: $32,075
Family Medicine $32,075
Richard Dombroski, Do, DO
Family Medicine — Payments: $25,077
Family Medicine $25,077